About
MPN Research Foundation

Partner. Advocate. Friend. At the MPN Research Foundation, we’re committed to standing with you in the fight against polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF) – the group of blood cancers collectively known as myeloproliferative neoplasms.

About Us

Providing education and resources for a better today. Investing in research for a better tomorrow.

MPNRF By the Numbers

  • $MM
    • MPN Research Funded
    • Researchers Supported
    • Projects Funded

Recent News

Breaking: Inrebic (Fedratinib) approved for Myelofibrosis! This becomes the first FDA approved drug for an MPN in nearly a decade

MPN News | August 16 2019

It is an oral kinase inhibitor with activity against wild type and mutationally activated Janus Associated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3).

Read More

ASH Awards the 2019 William Dameshek Prize

MPN News | 8/8/19

The American Society of Hematology presented Emmanuelle Passegué, Ph.D., of Columbia University Irving Medical Center in New York City with the 2019 William Dameshek Prize for her outstanding contribution to the field of hematology.

Read More

CPI-0610 Demonstrates Activity in MF Patients After Ruxolitinib Failure

MPN News | 08/01/19

A researcher at Mt. Sinai in this video discusses observations from their clinical trial with the drug CPI-0610.

Read More
More News

What is Primary Myleofibrosis (MF)?

Primary Myleofibrosis (MF)

PMF is a chronic blood cancer in which excessive scar tissue forms in the bone marrow and impairs its ability to produce normal blood cells.

Learn about PMF

What is Essential Thrombocythemia (ET)?

Essential Thrombocythemia (ET)

Most commonly diagnosed in women over the age of 50, ET is associated with a proliferation of platelet precursors in the bone marrow and complications frequently include blood clotting and/or bleeding.

Learn about ET

What is Polycythemia Vera (PV)?

Polycythemia Vera (PV)

The disease is most common in men over the age of 60, but anyone can develop PV. PV patients typically experience an elevated red blood cell count, an elevated platelet count and an enlarged spleen, especially over time.

Learn about PV

Patient Stories

See All Patient Stories

Diane Hilton Essential Thromobocythemia (ET)

Meet MPN patient Diane Hilton and read about her 31-year journey with Interferon.

Meet Diane Hilton

Ryan Tellini's Journey with Interferon Myelofibrosis (MF)

Learn about MF patient Ryan Tellini and his journey with Interferon.

Meet Ryan Tellini's Journey with Interferon

Linda Reekie Polycythemia Vera (PV)

Meet PV patient, Linda Reekie from Port St. Lucie, FL

Meet Linda Reekie

Nancy Francis Essential Thromobocythemia (ET)

Meet ET patient, Nancy Francis from Gander Bay, Newfoundland

Meet Nancy Francis

Jessica Harshbarger Essential Thromobocythemia (ET)

Meet ET patient, Jessica Harshbarger from Chicago, IL

Age: 42 Meet Jessica Harshbarger

Jen Hawkins Essential Thromobocythemia (ET)

Meet ET patient, Jen Hawkins from Tri-Cities, Washington

Age: 31 Meet Jen Hawkins

With an orphan disease, the support can be hard to find. I found that support at the MPN Research Foundation.

Juan Alderete, PV 06

Ready to do more?

Julie and her family joined team MPN and created HikeMF to join the fight against MPNs.

Get Involved Now.

Stay Connected

With your generous gift, you can change a MPN patient's prognosis.

By supporting MPN Research Foundation, you're also supporting countless doctors and researchers around the world who are working to find a cure for these rare diseases.

Donate Now

Join Cancer Connect

A safe space to chat with others living with PV, ET and MF

Start here!

MPN Community Calendar

HIKEMF
Sat, May 21st, 10am

Attend the Event

MPN Information kit

Be the first to know about what's going on in the PV, ET, and MF community.

Get the Kit